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This study was performed to investigate the clinical and
pathologic features of C4d-positive steroid-resistant acute
rejection (AR) at different phases after renal transplantation.
Fifty-six kidney allograft recipients with C4d-positive AR were
divided into three groups, very early rejection (VER, occurring
p14 days following transplantation, n¼ 28), early rejection
(ER, occurring 15–180 days following transplantation, n¼ 5),
and late rejection (LR, occurring 4180 days following
transplantation, n¼ 23). Clinical and pathological features
were evaluated. Significantly more patients in the ER and LR
groups were associated with a reduction or withdrawal of
immunosuppressants. More patients in the ER and LR groups
experienced a significant (43 g/l) decrease in serum albumin
(80% ER, 91.3% LR, 7.1% VER, Po0.001) and a decrease in
hemoglobin (41 g/dl) (80, 100 vs 17.9%, Po0.001). Most VER
patients reported a fever and had very rapid graft
dysfunction requiring dialysis. Significantly more patients
(87%) had interstitial fibrosis and tubular atrophy in the LR
group compared with the other groups and 13% had
transplant glomerulopathy. Most cases of VER were reversed
with tacrolimus and mycophenolate mofetil treatment, with
or without immunoadsorption, with a 1-year survival rate of
96.4%, compared with only 60 and 52.2% in the ER and LR
groups. In conclusion, C4d-positive steroid-resistant AR at
different time points is associated with unique clinico-
histopathological manifestations requiring distinct treatment
strategies. Late episodes are usually associated with
significantly reduced serum albumin and hemoglobin levels
and a poorer outcome. A more specialized treatment
protocol should be established for these patients.
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Alloantibody-mediated acute rejection (AR) is an important
cause of renal allograft loss after renal transplantation.1–4
Peritubular capillaries (PTC) C4d deposition was found to
have 95% sensitivity and 96% specificity for circulating anti-
donor antibodies, and is regarded as a marker for antibody-
mediated rejection (AMR) after renal transplantation.5 It has
even been proposed that an early post-transplant biopsy
displaying diffuse C4d-positive staining is suggestive of AMR,
even in the absence of detectable serum anti-HLA (human
leukocyte antigen) antibodies.6 Furthermore, in a previous
retrospective study,7 we found that AMR episodes occurring
during the first 2 weeks after transplantation were usually
associated with a better outcome than those occurring after
this time, and thus constitute a separate entity.
In contrast, late AR is defined as an episode of cellular
rejection that occurs over 3 or 6 months after transplanta-
tion, and is associated with a poorer outcome than earlier
episode.8–10 However, Poduval et al.11 detected PTC C4d
staining in renal allograft in late AR (X6 months post-
transplantation), and found that more than 40% displayed
evidence of humoral rejection, which contributes signifi-
cantly to graft loss. Therefore, it appears that AMR can occur
at all time points post-transplantation.
Our study was performed to determine the clinical and
pathologic features of AMR at different time periods after
transplantation. Based on previous findings,7–11 we divided
all cases into to three groups, very early rejection (VER,
occurring 1–14 days after transplantation), early rejection
(ER, occurring 15–180 days after transplantation), and late
rejection (LR, occurring 4180 days after transplantation).
RESULTS
Baseline characteristics
Fifty-six patients were diagnosed as having C4d-positive
steroid-resistant AR during the study period (Figure 1). They
were divided into three groups according to the time of onset
of rejection: VER (n¼ 28), ER (n¼ 5), and LR (n¼ 23). The
baseline characteristics of all the recipients are listed in
Table 1. There was no significant difference among three
groups in terms of donor age, recipient gender, and baseline
immunosuppressants, apart from that more recipients in the
VER group than in the other groups received interleukin-2
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receptor (IL-2R) monoclonal antibody induction. Signifi-
cantly more recipients with positive panel reactivity anti-
bodies (PRA) were found in the VER group compared with
the ER and LR groups (39.3, 0, 8.7%, respectively, Po0.05).
Clinical manifestations
Compared with patients in the VER group, significantly more
patients in the ER and LR groups were associated with a
reduction or withdrawal of one or more immunosuppres-
sants Po0.001; Table 2), which were associated with non-
compliance. All patients had signs of renal allograft
dysfunction, such as a decrease in urine volume or elevated
serum creatinine. However, in the VER group, significantly
more patients reported a decrease in urine volume to less
than 1000 ml/day compared with patients in the ER and LR
groups (Po0.001). In the VER group, 75% of patients
required dialysis within 2 weeks of the onset of rejection,
compared with 40 and 17.4% in the ER and LR groups,
respectively (Po0.01). Compared with the VER group,
significantly decreased levels of hemoglobin and serum
albumin were seen in the ER and LR groups. Only 7.1%
patients in the VER group had a decrease of serum albumin
over 3 g/l, but it was 80% in the ER group and 91.3% in the
LR group. With regard to hemoglobin levels, 100% of
patients in the LR group, 80% of patients in the ER group,
and 17.9% of patients in the VER group had a decrease of
more than 1 g/dl (Po0.001) (Figure 1). The reporting of
fever was significantly higher in the VER group compared
with the LR and ER groups (Po0.001; Table 2).
Pathology findings
A comparison of histological lesions in the three groups is
given in Table 3. Neutrophil and mononuclear cell inflam-
mation in the PTC area and glomerulus was common in all
three groups. Tubulitis was seen in 80% of early biopsies and
78% of late biopsies, compared with 42.9% of very early
biopsies. This is similar to the incidence of interstitial
infiltration. However, a lack of interstitial infiltrates was
correlated with the use of IL-2R monoclonal antibody in the
Table 1 | Clinical data of renal allograft recipients with C4d-positive steroid-resistant acute rejection
VER (n=28) ER (n=5) LR (n=23) P-value
Age (years) 40.477.5 29.074.9 44.2710.9 0.004
Gender (male/female) 11/17 4/1 14/9 0.134
PRA positive 11 (39.3) 0 (0) 2 (8.7) 0.022
Age of donor (years) 28.975.9 28.474.3 29.176.5 0.972
Prior renal transplantation 1 (3.6) 0 (0) 1 (4.3) 1.000
Prior acute rejection 0 (0) 0 (0) 5 (21.7) 0.025
Baseline immunosuppressants
MMF+CsA+Pred 15 (53.6) 1 (20.0) 10 (43.5) 0.412
MMF+Tac+Pred 13 (46.4) 4 (80.0) 8 (34.8) 0.208
Aza+CsA+Pred 0 (0) 0 (0) 5 (21.7) 0.025
IL-2 mAb induction 9 (32.1) 0 (0) 0 (0) 0.004
Aza, azathioprine; CsA, cyclosporine; ER, early rejection; IL-2 mAb, interleukin 2 monoclonal antibody; LR, late rejection; MMF, mycophenolate mofetil; PRA, panel reactive
antibody; Pred, prednisone; Tac, tacrolimus; VER, very early rejection.
Table 2 | Clinical manifestations of renal allograft recipients with C4d-positive steroid-resistant acute rejection.
VER (n=28) ER (n=5) LR (n=23) P-value
Onset of rejection post-surgery 9.777.1d 84.0735.7d 49.9737.9mon —
Reduce or withdraw immunosuppressants before rejection 0 (0) 3 (60.0) 12 (52.2) o0.001
Fever (%) 20 (71.4) 1 (20) 2 (8.7) o0.001
Urine volume o1000 ml/day (%) 27 (96.4) 2 (40.0) 2 (8.7) o0.001
Elevated serum creatinine (n (%)) 28 (100) 5 (100) 23 (100) —
Need of dialysis within 2 weeks of rejection 21 (75.0) 2 (40.0) 4 (17.4) o0.001
Decrease in hemoglobin (41 g/dl) 2 (7.1) 4 (80.0) 23 (100) o0.001
Decrease in serum albumin (43 g/l) 3 (10.7) 4 (80.0) 21 (91.3) o0.001
ER, early rejection; LR, late rejection; VER, very early rejection.
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Figure 1 | Variation of serum albumin and hemoglobin during
acute rejection episodes compared with pre-rejection periods.
(a) Variation of serum albumin; (b) variation of hemoglobin. VER, very
early rejection group; ER, early rejection group; LR, late rejection group.
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VER group. The incidence of interstitial infiltrates was 11 vs
53% (Po0.05) and for tubulitis it was 11 vs 58% (Po0.05)
for those who had, compared with those who had not,
received antibody inductions. Significantly more patients
(87%) have interstitial fibrosis and tubular atrophy in the LR
group compared with either of the other two groups, and
13% of patients in the LR group had transplant glomerulo-
pathy, which was not found in the other two groups. We did
not find significant differences in the incidence of other
lesions, such as intimal ateritis, interstitial hemorrhage, and
plasma cell infiltration. According to Banff ’97 classification,
more episodes in the LR than ER and VER groups met the
criteria for grade II or III rejection. We did not find any
significant relationship between the Banff type of AR and
clinical parameters examined in each group.
Rescue treatment and clinical outcome
Once a rejection episode occurred, the patient received bolus
corticosteroid therapy (methylprednisolone 500 mg/day for 3
days) as first-line treatment. Patients were also administered
tacrolimusmycophenolate mofetil (MMF) treatment (ta-
crolimus trough levels maintained to 8–15 ng/ml; MMF 1.5 g/
day) at the same time as corticosteroid therapy. In six
episodes of rejection that were diagnosed between August
2002 and March 2003, immunoadsorption (IA) was added to
rescue therapy; this was standard in our unit for treating
steroid-resistant rejection in that period. It was performed
with the Citem 10 Immunoadsorption System and staphylo-
coccal protein A column (Fresenius Haemo Care Inc.,
Redmond, WA, USA).7
Overall, 64.3% of rejection episodes were reversed (44.6%
were completely reversed and 19.6% were partially reversed),
16.1% were controlled, and 19.6% lost their graft and
returned to dialysis within a month. The 1-year survival rate
for patients was 100%. However, the outcome of rejection
episodes differed between the three groups. In the VER
group, 96% of episodes were reversed and only one patient
lost their graft. But in the ER group, only 40% of episodes
were partially reversed and one was controlled; the other
two patients lost their graft and returned to dialysis. The
outcome of LR group was even poorer. It appears that
tacrolimusMMF treatment did not have the same positive
effects in the ER nor in the LR group. Of the 12 patients who
received tacrolimusMMF treatment, only seven were
controlled and five lost their grafts. Intending to find a more
efficiency protocol, some other strategies were also attempted
in the LR group. Mycophenolate mofetil (increased to 1.5
from 1.0 g/day) with sirolimus (6 ml for the first day,
followed with 2 ml/day, with a target level of 8–12 ng/ml)
was administered to two patients, but both returned to
dialysis within 1 month. One patient who received IA in
addition to tacrolimusMMF also had loss of graft. Eight
patients received an increased dose of MMF. The dose was
increased to 1.5–2.0 g/day from the usual 1.0–1.25 g/day,
which is sufficient for Chinese renal allograft recipients at 6
months post-transplantation. Of these patients, three were
controlled and five had partial reversal of rejection (Table 4).
The 1-year graft survival after rejection was 96.4% in the VER
group, compared with only 60% in the ER group and 52.2%
in the LR group (Figure 2).
DISCUSSION
Previous studies have suggested that the time to onset of
AMR may be associated with graft outcomes.7,11 In the
present study, we investigated the clinical and pathologic
manifestations of C4d-positive, steroid-resistant AR occur-
ring in different time periods after renal transplantation. To
clearly differentiate the timing of rejection, we arbitrarily
divided rejection episodes into three groups based on
findings from previous studies.7–11 As donor-specific anti-
bodies (DSA) were not detected in this cohort, we used
C4d-positive steroid resistance as a diagnostic criterion for
Table 3 | Histological lesion of renal allograft with C4d-positive steroid-resistant acute rejection
VER (n=28) ER (n=5) LR (n=23) P-value
Mononuclear cell infiltration in the peritubular capillary area (n (%)) 27 (96.4) 3 (60.0) 20 (87.0) 0.066
Neutrophil infiltration in the peritubular capillary area (n (%)) 24 (85.7) 3 (60.0) 13 (56.0) 0.052
Glomerulitis with neutrophils (n (%)) 15 (53.6) 2 (40.0) 11 (47.8) 0.824
Glomerulitis with mononuclear cells (n (%)) 25 (89.3) 4 (80.0) 17 (73.9) 0.284
Small vessel thrombi 4 (14.3) 2 (40.0) 4 (17.4) 0.383
Tubulitis (n (%)) 12 (42.9) 4 (80.0) 18 (78.3) 0.026
Interstitial infiltrate (n (%)) 11 (39.3) 4 (80.0) 21 (91.3) o0.001
Intimal ateritis (n (%)) 24 (85.7) 3 (60.0) 15 (65.2) 0.133
Interstitial fibrosis (n (%)) 0 (0) 1 (20.0) 20 (87.0) o0.001
Transplant glomerulopathy (n (%)) 0 (0) 0 (0) 3 (13.0) 0.128
Tubular atrophy (n (%)) 0 (0) 1 (20.0) 11 (47.8) o0.001
Interstitial hemorrhage (n (%)) 10 (35.7) 3 (60.0) 5 (21.7) 0.206
Plasma cell infiltrate (n (%)) 7 (25.0) 3 (60.0) 10 (43.5) 0.186
Banff 97 Grade
I 4 (14.3) 0 (0) 10 (43.5) 0.031
II 22 (78.6) 4 (80.0) 12 (52.2) 0.107
III 2 (7.1) 1 (20.0) 1 (4.3) 0.399
ER, early rejection; LR, late rejection; VER, very early rejection.
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AMR, according to previously reported results.6,11 Because
of the high sensitivity and specificity of C4d deposition
for circulating DSA,5 we believe that the detection of
C4d deposition combined with steroid resistance reflects
AMR. In the present study, we detected a very high incidence
of neutrophil infiltration in PTCs; this may be due to
the fact that all rejection episodes included were resistant
to steroids.
The occurrence of C4d-positive AR during the first 2
weeks after transplantation may be regarded as a relatively
unique entity compared with episodes occurring after this
time. Half of all episodes occurred during this short period of
time. The extremely high incidence in this short period
suggests that there is a potentially distinctive pathogenesis
associated with these AR episodes. Compared with episodes
occurring at a later time, significantly more patients
experiencing C4d-positive AR in the first 2 weeks after
transplantation were associated with positive pretransplant
PRA. All patients developed dramatic allograft dysfunction
and most had to undergo dialysis within 2 weeks of rejection.
In this particular group of patients, fewer episodes of
tubulitis and interstitial infiltrations were detected compared
with patients who had graft rejection at a later stage. This
may have been caused by the use of IL-2 monoclonal
antibodies before transplantation in the VER group. How-
ever, this group presented with clinical and histological
manifestation, typical of ‘classical’ AMR. Although most
episodes of AR are steroid resistant, they were usually
associated with good graft outcomes when treated with
tacrolimusMMF with or without IA, in agreement with our
previous findings.7
From our study, it appears that C4d-positive AR occurring
over 6 months after transplantation might be regarded as a
separate subgroup to the early C4d-positive AR episodes.
From our results, it appears that late C4d-positive ARs seem
to be mostly associated with the withdrawal or reduction of
immunosuppressants, rather than positive pretransplant
PRA. In this group, the clinical manifestations were more
moderate. The rise in serum creatinine was slower in the LR
group compared with the VER group, and fever and a large
reduction in urine volume were not common in the LR
group. However, the only different histological manifesta-
tions we found were that most biopsies had interstitial
fibrosis and tubular atrophy. Chronic interstitial and tubular
lesions may account for why most patients did not experience
a decrease of urine volume. Although more episodes in the
LR group met Banff criteria for grade I AR, these episodes
were usually associated with poorer outcomes than in the
VER group. Late episodes were not only resistant to bolus
steroids and other T-cell-specific reagents, but they also did
not achieve a good response with tacrolimusMMF treat-
ment. More than 1/3 of all patients lost their grafts and the
1-year graft survival rate was only 52.2%. Taken together,
these evidences suggest that an AMR that occurs more than 6
months after transplantation is different from the one that
occurs during the first 2 weeks after transplantation.
The current study has raised the question of whether the
C4d-positive AR observed in the VER and LR groups is
associated with different mechanisms. It is well accepted that
AMR can be caused by both pre-existing DSA and de novo
DSA. A high level of pre-existing DSA can cause hyperacute
rejection and cause instant loss of a kidney graft.12 With the
improvement of crossmatching techniques and the use of
more aggressive therapies, the incidence of hyperacute
rejection has reduced. However, very low levels of DSA,
especially HLA-II-reactive antibodies, can cause severe post-
transplant AMR.13,14 We speculate that low levels of pre-
existing DSA are a contributing factor to AMR occurring
during the first 2 weeks after transplantation. As the half-life
of the average antibody is B20 days,15 the level of pre-
existing DSA gradually diminishes. We therefore propose that
Table 4 | Outcomes of C4d-positive steroid-resistant acute rejection at different time periods
VER (n=28) ER (n=5) LR (n=23) P-value
Reversed 27 (96.4) 2 (40.0) 7 (30.4) o0.001
Complete reversal (%) 25 (89.3) 0 (0) 0 (0) o0.001
Partial reversal (%) 2 (7.1) 2 (40.0) 7 (30.4) 0.115
Controlled 0 (0) 1 (20.0) 8 (34.8) 0.003
Loss of graft (%) 1 (3.6) 2 (40.0) 8 (34.8) 0.010
One-year graft survival after rejection (%) 27 (96.4) 3 (60.0) 12 (52.2) o0.001
One-year recipient survival after rejection (%) 28 (100) 5 (100) 23 (100) —
ER, early rejection; LR, late rejection; VER, very early rejection.
Complete reversal: graft function recovered to within the normal range (o1.2 mg/dl) within 1 month of rescue therapy; partial reversal: graft function improved but did not
recover to the normal range within 1 month of rescue therapy; controlled: graft function did not improve but had stable function without dependence on dialysis; loss of
graft: the recipient returned to dialysis owing to graft rejection within 1 month after the rejection.
Time (months)
50403020100
G
ra
ft 
su
rv
iva
l r
at
e
1.0
0.9
0.8
0.7
0.6
0.5
Late episodes 
Early episodes 
Very early episodes 
Figure 2 | Graft survival after rejection episodes. Significantly
more patients lost grafts during the 6 months after rejection in the
early and late groups compared with the very early group.
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AMR occurring more than 2 weeks after transplantation is
mainly associated with de novo rather than pre-existing
antibodies. As the development of DSA can be inhibited with
current immunosuppressive therapies, this may explain why
most late episodes are associated with withdrawal or a
reduction in immunosuppressive therapy.
With regard to episodes occurring between 15 days and 6
months after transplantation, it can be speculated that most
are associated with de novo DSA. Both the clinical course and
histologic manifestations are similar to those episodes
occurring after 6 months. We therefore suggest that it is
reasonable to divide AMR into two groups according to the
onset of rejection; the threshold would be 15 days (or up to
1 month) after transplant surgery. This would assist in the
selection of an optimal treatment method. Early episodes can
be treated with tacrolimusMMF, combined with IA,
plasmapheresis, or intravenous immunoglobulins or not,
for instance.7,16–18 With regard to late episodes, it appears
that the simple combination of tacrolimus and MMF is not
sufficient to reverse the rejection; the optimal method
remains to be defined. However, the role of MMF in the
treatment of this kind of rejection is worthy of further
investigation.
It is very interesting to note that all patients in the LR
group experienced significantly reduced serum albumin and
hemoglobin levels (Figure 1). Both serum albumin and
hemoglobin levels decreased dramatically when the rejection
occurred, which suggested that this may be associated with an
immunologic course. Serum albumin levels can recover to the
normal range within a few weeks after control of rejection,
whereas hemoglobin levels remain at a low concentration for
a very long period, usually several months. In VER group, we
also observed reduced serum albumin and hemoglobin levels
in some cases, but the variations were very slight and could
be explained by the overload of body fluid resulting from
decreased urine output.
Serial manifestations associated with late AMR (including
aggressive renal dysfunction without decrease in urine
output, significantly reduced levels of serum albumin and
hemoglobin, resistance to bolus steroid and other anti-
T-lymphocyte treatments) are very common and mostly
occur in tandem. We propose to define these manifestations
as a syndrome, perhaps termed ‘late-AMR syndrome’. This
‘syndrome’ is quite different from that of early AMR episodes
(Table 5). However, the detailed mechanisms of this
syndrome remain to be defined. Most LR episodes share
the histological manifestation of interstitial fibrosis, and this
lesion may help to explain the continuous anemia that occurs
after rejection, but not the rapid graft dysfunction and poor
outcome compared with ER episodes. It has been reported
that interstitial fibrosis and tubular atrophy occur to the same
extent in C4d-positive and C4d-negative late AR, but that the
outcomes are very different. The new concept of ‘accom-
modation’,17,19,20 which is defined as the resistance of a graft
to the acute pathological effects of graft-specific antibodies
and complement fixation, may account at least in part for
why allograft dysfunction and histological lesions in the LR
group were not as rapid as in the ER group.
It appeared that the clinical course of patients in the VER
group was similar to that of patients with acute tubular
necrosis associated with ischemia–reperfusion injury. How-
ever, C4d staining was not observed in ischemia or
ischemia–reperfusion injury in perioperative renal transplant
biopsies, even in those of cadaveric grafts with cold ischemia
times as long as 41 h.21 Acute tubular necrosis is usually
associated with activation of the alternative, but not the
classical, pathway of complement.22 Thus, C4d should not be
detected in patients with acute tubular necrosis as only the
alternative complement pathway is activated in these
patients. C3 rather than C4 is involved in this pathway.
However, in the present study, we used C4d positivity and
steroid-resistant AR as enrollment criteria; therefore, this
explanation is not perfect, and may vary at time points after
transplantation. A prospective study based on the standard
diagnosis criteria for AMR may help to determine whether
this theory is true.
In conclusion, AMR episodes in different periods after
renal transplantation are associated with different clinico-
histopathological manifestations and need to be treated
differently. Late episode is usually associated with signifi-
cantly reduced serum albumin and blood globulin and a
poorer outcome. It is turning to be an important course to
graft loss. A more specialized protocol should be established
for these patients.
Table 5 | An overview of C4d-positive steroid-resistant acute rejection at different time periods
0–14 days 414 days
Main risk factor Positive panel reactivity antibody before transplantation,
including factors causing sensitization
Withdrawal or reduction of immunosuppressants.
Non-compliance with immunosuppressive therapy
Antibody involved Mostly pre-existing donor-specific antibodies Mostly de novo donor-specific antibodies
Clinical syndrome Very rapid graft dysfunction; significantly decreased
urine output
Aggressive renal dysfunction without decrease in urine
output; significantly reduced serum albumin and
hemoglobin levels
Pathological manifestations Mixed Mixed, mostly combined with interstitial fibrosis and
tubular atrophy.
Treatment Tacrolimus+MMF, with or without IA, PPH, IV-IG To be established
Outcome Good Poor
IA, immunoadsorption; IV-IG, intravenous immunoglobulins; MMF, mycophenolate mofetil; PPH, plasmapheresis.
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MATERIALS AND METHODS
Patients
Between July 1999 and June 2005, 685 cadaveric renal transplanta-
tions were performed in Jinling Hospital, Nanjing University School
of Medicine. Among them, 56 recipients were diagnosed as having
C4d-positive steroid-resistant AR episodes according to clinical
manifestations and histological features. The diagnosis was based on
the following: (1) clinical evidence of AR, manifested as rapid renal
dysfunction and/or decrease of urine volume, resistant to steroid
treatment; (2) C4d deposition in the PTC area; and (3) pathologic
features that met Banff ’97 criteria for AR grade I, II, or III. Steroid-
resistant rejection was defined as serum creatinine levels that did not
return to within 20% of baseline within 5 days after the last
methylprednisolone pulse. Pretransplant PRA activity was assessed
by using a panel of cells from 50 phenotyped donors before 2000; a
flow-PRA screening test was performed prior to transplantations
carried out since 2001, according to the guidelines provided by the
supplier (One Lambda Inc., Canoga Park, CA, USA), as described by
Bo¨hmig et al.23 Sera with 410% flow-PRA class I and/or II
reactivity were considered anti-HLA antibody-positive. Pretrans-
plant cytotoxic crossmatch testing was performed according
to the protocol of the Eurotransplant Organization, using the
standard microcytotoxicity technique described by Terasaki
and McClelland.24
Renal allograft pathology and C4d staining
Two needle biopsy cores were obtained from each renal allograft for
morphologic studies. These were divided into two parts: one for
formalin fixation and one for quick freezing. Hematoxylin and
eosin, periodic acid Schiff, and masson trichrome stains were
routinely used for formalin-fixed tissue. Fresh-frozen tissue was
analyzed by immunofluorescence microscopy using a conventional
panel of antibodies against immunoglobulin (Ig) G, IgM, IgA,
complement component (C)3, C4, and C1q. C4d staining was
routinely performed on frozen slides, using an indirect immuno-
fluorescence technique with a primary affinity-purified monoclonal
antibody (mouse anti-human; dilution 1:50; 1.5 h incubation at
room temperature; Quidel, San Diego, CA, USA) and a fluorescein
isothiocyanate-labeled affinity-purified secondary rabbit anti-mouse
IgG antibody (1:20; 40-min incubation at room temperature;
DAKO, Glostrup, Denmark). Staining was performed according to
standard procedures. All biopsies met the Banff criteria for
adequacy; no fewer than 10 glomeruli and two arterial sections
were available on one slide. Positive C4d staining was defined as
bright linear staining along capillary basement membranes, invol-
ving over half of sampled capillaries according to international
consensus criteria based on discussions at the sixth Banff Conference
on Allograft Pathology in 2001.25
Initial immunosuppression
Primary immunosuppressive protocols consisted of azathiopurine,
MMF (CellCepts), cyclosporine A (CsA), tacrolimus, and steroid.
Two doses of anti-IL-2R monoclonal antibodies, such as basiliximab,
daclizumab, were also used timely as induction therapy. Since 2000,
MMF was substituted for azathiopurine as initial treatment for
newly transplanted patients. The selection of the protocol and
induction was based on the pretransplantation PRA and crossmatch.
The IL-2R antibodies are preferred in patients with a high PRA, such
as pre-gravid female subjects, the young, or patients at high risk of
rejection. However, some patients in China are unable to cover the
high cost of treatment; therefore, their circumstances were taken
into account. The initial dose of MMF was 1.5 g/day, as a previous
study had shown that Chinese patients required lower doses of
immunosuppressants than the 2 g/day that is currently indicated in
other populations.26 Calcineurin inhibitors were added when the
serum creatinine level decreased to 50% of pretransplant levels.
Tacrolimus was initiated at a dose of 0.6 mg/kg day, and CsA was
initiated at 4 mg/kg day; doses of both agents were increased
gradually according to the recovery of graft function. The doses of
tacrolimus and CsA were adjusted to trough levels; we aimed for a
target trough level of 8 ng/ml for tacrolimus and 200 ng/ml for CsA
before day 7 post-surgery. During the first 6 months after surgery,
the tacrolimus dose was maintained at 6–12 ng/ml and at 4–8 ng/ml
thereafter, whereas the CsA dose was maintained at 150–250 ng/ml
during the first 6 months and 100–200 ng/ml thereafter. A
corticosteroid tapering regimen standard in Chinese recipients was
used, consisting of an intravenous bolus of methylprednisolone
500 mg on days 0–2, followed by oral prednisone 80 mg/day
on day 3, and the dose was tapered 10 mg/day to 20 mg/day,
and then tapered slowly to 5 mg/day thereafter. The target range of
the mycophenolic acid area under the curve (AUC0–12) was
45–60 mg/ml h.
Clinical observation
The following clinical parameters were observed: (1) patient age at
the time of transplantation; (2) patient gender; (3) cold ischemic
time; (4) serum PRA levels; (5) underlying renal disease; (6) onset of
rejection, defined as the time from the transplant to the onset of
clinical manifestation suggesting rejection (such as a rise in serum
creatinine or a decrease in urine volume); (7) histological
manifestations; (8) graft tissue C4d staining; (9) immunofluores-
cence features; (10) immunohistochemistry manifestations; (11)
baseline and follow-up serum creatinine levels; (12) treatment and
outcomes; and (13) graft survival rate at 1 year and long-term
outcomes. All patients were under serious follow-up for no less than
1 year, including patients who lost their grafts.
The effect of rescue therapy was categorized into the following
groups: complete reversal, partial reversal, controlled, and lost graft.
Complete reversal meant that graft function recovered to the normal
range (o1.2 mg/dl in our department) within 1 month of rescue
therapy; partial reversal meant that graft function improved but did
not recover to the normal range within 1 month; controlled meant
that graft function did not improve but remained stable without
dependence on dialysis in the first month; graft loss meant that the
recipient returned to dialysis owing to rejection within 1 month
after the rejection.
Statistical analysis
Analysis of data was carried out using the Stata 6.0 (Stata
Corporation, College Station, TX, USA). Descriptive data are
expressed as the mean7s.d.; the analysis of variance was determined
using analysis of variance. A w2 test was used for assessing the
significance of categorical variables. Statistically, Po0.05 was taken
as the significant level. Analysis of graft survival was performed
using the Kaplan–Meier method using SPSS10.0 for Windows (SPSS
Inc., USA, 1999).
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